Who
Thomas K. Equels
CEO & President
Company insider
Files Form 4 as: CEO & President, AIM ImmunoTech.
In numbers
- Trades disclosed
- 145
- Buys
- 58
- Sells
- 0
- Bought
- $1.1M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Jan 2009
- Last trade
- 17 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 18 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $4,99224,000 at $0.208 | filing |
| 17 Sep 2026filed 18 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $5,04024,000 at $0.21 | filing |
| 16 Sep 2026filed 17 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $2,31011,000 at $0.21 | filing |
| 16 Sep 2026filed 17 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $2,31011,000 at $0.21 | filing |
| 15 Sep 2026filed 16 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $4,86222,000 at $0.221 | filing |
| 15 Sep 2026filed 16 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $4,84022,000 at $0.22 | filing |
| 14 Sep 2026filed 15 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $1,2925,900 at $0.219 | filing |
| 14 Sep 2026filed 15 Sep 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $1,2985,900 at $0.22 | filing |
| 12 Mar 2026filed 16 Mar 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Code C | —25,000 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | AIM AIM ImmunoTechoption or derivative · Biotechnology | SEC FORM 4 Code C | —25 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | AIM AIM ImmunoTechoption or derivative · Biotechnology | SEC FORM 4 Code C | —25 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Code C | —25,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | AIM AIM ImmunoTechoption or derivative · Biotechnology | SEC FORM 4 Code J | $625K25 at $25,000.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | AIM AIM ImmunoTechoption or derivative · Biotechnology | SEC FORM 4 Code J | —50,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | AIM AIM ImmunoTechoption or derivative · Biotechnology | SEC FORM 4 Code J | $625K25 at $25,000.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | AIM AIM ImmunoTechoption or derivative · Biotechnology | SEC FORM 4 Code J | —50,000 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $824107 at $7.70 | filing |
| 12 Jun 2025filed 13 Jun 2025 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $896103 at $8.70 | filing |
| 11 Apr 2025filed 23 Apr 2025 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $59K1,968,504 at $0.03 | filing |
| 4 Apr 2025filed 7 Apr 2025 | AIM AIM ImmunoTechBiotechnology | SEC FORM 4 Bought | $2,46041,000 at $0.06 | filing |
News
AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysAIM · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Thomas K. Equels; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.